



Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016

Weekending:- 03-02-2017

Legal Publication Date:- 09-02-2017

Journal Code (170209)

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

30-01-2017		
63/2017	F. HOFFMANN-LA ROCHE AG Switzerland (Priority 02-02-2016 EP)	“Pyrazol-pyridine derivatives”
64/2017	BAYER CROPSCIENCE AKTIENGESELLSCHAFT Germany (Priority 11-02-2016 EP)	“SUBSTITUTED 2-OXYIMIDAZOLYLCARBOXAMIDES AS PESTICIDES”
65/2017	BAYER CROPSCIENCE AKTIENGESELLSCHAFT Germany (Priority 11-02-2016 EP)	“SUBSTITUTED IMIDAZOLYLCARBOXAMIDES AS PESTICIDES”
66/2017	BEIJING SPC ENVIRONMENT PROTECTION TECH CO. LTD, China	“ROTATIONAL FLOW AND SIN K FLOW-COUPPLING INTEGRATED SYSTEM FOR ULTRA-CLEAN DERSULPHURATION AND DEDUSTING AND DESULPHURATION AND DEDUSTING METHOD THEREFOR”
31-01-2017		
67/2017	Shamoon Al Islam Dr. Yasir Jamil Zunaira Javaid Faisalabad – Pakistan	“High Frequency Electromagnet Driver for Hyperthermia Application”
01-02-2017		
68/2017	Syngenta Participations AG Switzerland	“Pesticidally active heterocyclic derivatives with sulphur containing substituents”

	(Priority 05-02-2016 EP)	
69/2017	BAYER CROPSCIENCE AKTIENGESELLSCHAFT Germany (Priority 11-02-2016 EP)	“SUBSTITUTED 2- (HET)ARYLIMIDAZOLYLCARBOXYAMIDES AS PESTICIDES”
70/2017	BAYER CROPSCIENCE AKTIENGESELLSCHAFT Germany (Priority 11-02-2016 EP)	“SUBSTITUTED IMIDAZOLYLCARBOXAMIDES AS PESTICIDES”
02-02-2017		
71/2017	CHIESI FARMACEUTICI S.p.A., Italy (Priority 04-02-2016 EP)	“PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS”
72/2017	VIIV HEALTHCARE UK (No.5) LIMITED, United Kingdom (Priority 04-02-2016 US)	“C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS”
73/2017	QUALCOMM INCORPORATED USA (Priority 03-02-2016 US)	“SYSTEM AND METHOD FOR ADJUSTING AN ANTENNA RESPONSE IN A WIRELESS POWER RECEIVER”
74/2017	Takeda Pharmaceutical Company Limited Japan (Priority 04-02-2016 JP)	“SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF”
03-02-2017		
75/2017	BAYER PHARMA AKTIENGESELLSCHAFT Germany THE BROAD INSTITUTE INC., USA	“COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT”

	DANA-FARBER INSTITUTE CANCER INC., USA (Priority 05-02-2016 US)	
76/2017	HERBST, ROBERT W. CHARI, RAVI V.J. LAMBERT, JOHN M. LAI KATHERINE C. VEIBY, OLE PETER HILDERBRAND, SCOTT A., USA (Priority 05-02-2016 US)	“GCC-TARGETTED ANTIBODY-DRUG CONJUGATES”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

601/2011	DOLBY LABORATORIES LICENSING CORPORATION. U.S.A.	"METHOD AND SYSTEM FOR CONTROLLING DISTORTION IN A CRITICAL FREQUENCY BAND OF AN AUDIO SIGNAL" H03G9/18. 142473 In some embodiments, a method and system for controlling distortion of the output of a miniature speaker by attenuating at least one critical frequency band of the input signal to be reproduced, using tuning parameters that have been predetermined where the critical frequency band is a frequency range of the speaker's frequency response in which Total Harmonic Distortion (THD) peaks. The distortion control is performed in a manner which allows an increase in the average loudness of the speaker's output without significantly increasing distortion. The tuning parameters include a center frequency and a bandwidth of the critical frequency band, and a power threshold value. In some embodiments, the system is a loudness maximizer configured to limit
----------	---	---

distortion of a speaker's output by limiting distortion in a critical frequency band using predetermined control parameters, and limit the dynamic range of the output signal and increase its perceived overall average loudness level.




FIG. 1

SEALING FEES DUE-

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of **Rs.4500/-** should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

Accepted No.	Applicant Name	Application No.
142425	SPRAY ENGINEERING DEVICE LIMITED India.	529/2007
142426	NOKIA TECHNOLOGIES OY, Finland.	19/2008
142427	DR. WAQAS WAHAB Pakistan.	1064/2008
142428	Andritz AG Austria.	934/2010
142429	Dow AgroSciences LLC. USA.	863/2011
142430	Syngenta Participations AG Switzerland. Syngenta Limited United Kingdom.	176/2012
142431	Dr. Ghulam Fareed Dr. Shahnaz Parveen, Pakistan.	835/2013
142432	UNILEVER PLC United Kingdom.	839/2014

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 142089 of 29/9/2003 Priority date 30/9/2012 (Europe). Granted to: - **BAYER AKTIENGESELLSCHAFT, a body corporate organized under the laws of the Federal Republic of Germany, of D-51368 Leverkusen, Federal Republic of Germany.**

In pursuance of an application received on 17/10/2016.

The following entry has been made in the Register of Patents:-

Bayer Intellectual Property GmbH, a body corporate organized under the laws of Federal Republic of Germany, of Alfred-Nobel-Straße 10, 40789 Monheim am Rhein, Germany, as proprietor by virtue of Deed of Assignment dated 5th September, 2016 made between BAYER AKTIENGESELLSCHAFT, as Assignor of the One Part and Bayer Intellectual Property GmbH, as assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **138186** of **13/5/2002** Priority date **15/5/2001** (Europe). Granted to: - **CLARIANT FINANCE (BVI) LIMITED**, of **Citco Building, Wickhams Cay, P.O. Box 662, RoadTown, Tortola, British Virgin Islands**.

In pursuance of an application received on 14/10/2016.

The following entry has been made in the Register of Patents:-

Archroma IP GmbH, (Swiss Company), located at Neuhofstrasse 11, 4153 Reinach, Switzerland, as proprietor by virtue of Deed of Assignment dated 12th September, 2016 made between **CLARIANT FINANCE (BVI) LIMITED**, as Assignor of the One Part and **Archroma IP GmbH**, as assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **139872** of **23/8/2007** Priority date **25/8/2006** (Germany). Granted to:
- **Clariant International Ltd**, and later on assigned to: **CLARIANT FINANCE (BVI) LIMITED**, of
Citco Building, Wickhams Cay, P.O. Box 662, RoadTown, Tortola, British Virgin Islands.

In pursuance of an application received on 14/10/2016.

The following entry has been made in the Register of Patents:-

Archroma IP GmbH, (Swiss Company), located at Neuhofstrasse 11, 4153 Reinach, Switzerland, as proprietor by virtue of Deed of Assignment dated 12th September, 2016 made between **CLARIANT FINANCE (BVI) LIMITED**, as Assignor of the One Part and **Archroma IP GmbH**, as assignee of the Other Part.

REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000

In the matter of Patent No. **142105** of **10/10/2006** Priority date **12/10/2005** (Europe). Granted to:
- **CLARIANT FINANCE (BVI) LIMITED**, of **Citco Building, Wickhams Cay, P.O. Box 662, RoadTown, Tortola, British Virgin Islands**.

In pursuance of an application received on 14/10/2016.

The following entry has been made in the Register of Patents:-

Archroma IP GmbH, (Swiss Company), located at Neuhofstrasse 11, 4153 Reinach, Switzerland, as proprietor by virtue of Deed of Assignment dated 12th September, 2016 made between **CLARIANT FINANCE (BVI) LIMITED**, as Assignor of the One Part and **Archroma IP GmbH**, as assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **139048** of **18/8/2004** Priority date **21/8/2003** (Switzerland). Granted to: - **Clariant International Ltd**, and later on assigned to: **CLARIANT FINANCE (BVI) LIMITED**, of **Citco Building, Wickhams Cay, P.O. Box 662, RoadTown, Tortola, British Virgin Islands**.

In pursuance of an application received on 14/10/2016.

The following entry has been made in the Register of Patents:-

Archroma IP GmbH, (Swiss Company), located at Neuhofstrasse 11, 4153 Reinach, Switzerland, as proprietor by virtue of Deed of Assignment dated 12th September, 2016 made between **CLARIANT FINANCE (BVI) LIMITED**, as Assignor of the One Part and **Archroma IP GmbH**, as assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **138766** of **29/01/2004** Priority date **31/01/2003** (Europe). Granted to:
- **Clariant International Ltd**, and later on assigned to: **CLARIANT FINANCE (BVI) LIMITED**, of
Citco Building, Wickhams Cay, P.O. Box 662, RoadTown, Tortola, British Virgin Islands.

In pursuance of an application received on 14/10/2016.

The following entry has been made in the Register of Patents:-

Archroma IP GmbH, (Swiss Company), located at Neuhofstrasse 11, 4153 Reinach, Switzerland, as proprietor by virtue of Deed of Assignment dated 12th September, 2016 made between **CLARIANT FINANCE (BVI) LIMITED**, as Assignor of the One Part and **Archroma IP GmbH**, as assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 142043 of 14/01/2005 Priority date 15/10/2004 (USA). Granted to:
- **Aventis Pharmaceuticals Inc. (a corporation organized under the laws of the State of Delaware), of 55 Corporation Drive, Bridgewater, New Jersey 08807, USA.**

In pursuance of an application received on 26/07/2016.

The following entry has been made in the Register of Patents:-

Aventisub LLC, of 3711 Kennett Pike, Suite 200, Greenville, Delaware, 19807 USA, as proprietor by virtue of merger of - Aventis Pharmaceuticals Inc, into Aventisub LLC, according to the Merger Agreement dated: 18th June, 2014.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 142361 of 7/5/2009 Priority date 14/5/2008 (Europe). Accepted in the name of: - **Urea Casale S.A.**, A Swiss company, of Via Giulio Pocobelli, 6 CH-6900 Lugano-Besso, **Switzerland**.

In pursuance of an application received on 12/6/2016.

The following entry has been made in the Register of Patents:-

CASALE SA, of Via Pocobelli 6, CH-6900 Lugano, Switzerland., as proprietor by virtue of merger of **UREA CASALE S.A.**, into **CASALE SA** according to the Merger Agreement dated: **24th April, 2014**.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 141932 of 25/11/2008 Priority date 27/11/2007 (Europe).
Accepted in the name of: - **AMMONIA CASALE S.A.,Via Giulio Pocobelli, 6 CH-6900
Lugano-Besso Switzerland.**

In pursuance of an application received on 01/08/2016.

The following entry has been made in the Register of Patents:-

CASALE SA, of Via Pocobelli 6, CH-6900 Lugano, Switzerland., as proprietor by
virtue of merger of **AMMONIA CASALE S.A,**into **CASALE SA** according to the Merger
Agreement dated: 24th April, 2014.

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE
OF ADDRESS IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 137954 dated 15/11/2001, Granted to:-**Credo Stahlwarenfabrik Gustab Kracht GmbH & Co. KG, of Schlagbaumer Strasse 35, 42653 Solingen, Germany.**

In pursuance of an application received on 24/02/2016.

The following entry has been made in the Register of Patents:-

The Business Address of the patentee has been changed to:- **“Rheinische Straße 36, D-42781 Haan, Germany.**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 142269 dated 24/5/2012, Priority Date: 24/5/2011 (Europe) accepted in the name of: - **Nycomed Pharma AS, Drammensveien 852, 1372 Asker, Norway.**

In pursuance of an application received on 30th November, 2016.

The following entry has been made in the Register of Patents:-

The name of the patentee has been changed to:-**Takeda AS, Drammensveien 852, 1383 Asker, Norway.**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. **142344** of **4/7/2008** Priority date **6/7/2007** (USA). Granted to: -
Accepted in the name of GlaxoSmithKline LLC (a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America), of One Franklin Plaza, 200 N. 16th Street, Philadelphia, Pennsylvania 19102, United States of America. And later on assigned to: Novartis Pharma AG, of Lichtstrasse 35, 4056 Basel, Switzerland.

In pursuance of an application received on **4/7/2016**.

The following entry has been made in the Register of Patents:-

Novartis AG, of Lichtstrasse 35, 4056 Basel, Switzerland, as proprietor by virtue of Deed of Assignment dated 2nd March, 2015 made between Novartis Pharma AG, as Assignor of the One Part and Novartis AG, as assignee of the Other Part.

REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000

In the matter of Patent No. **142344** of **4/7/2008** Priority date **6/7/2007** (USA). Granted to: -
Accepted in the name of GlaxoSmithKline LLC (a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America), of One Franklin Plaza, 200 N. 16th Street, Philadelphia, Pennsylvania 19102, United States of America.

In pursuance of an application received on **4/7/2016**.

The following entry has been made in the Register of Patents:-

Novartis Pharma AG, of Lichtstrasse 35, 4056 Basel, Switzerland, as proprietor by virtue of Deed of Assignment dated **2nd March, 2015** made between **GlaxoSmithKline LLC**, as Assignor of the One Part and **Novartis Pharma AG**, as assignee of the Other Part.

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 141786 dated 4/12/2008, Priority Date: 6/12/2007 (Europe) Granted to: - **Tibotec Pharmaceuticals Ltd, of Eastgate Village Eastgate, Little Island Co Cork Ireland. And later on company name was changed to: “Tibotec Pharmaceuticals”**

In pursuance of an application received on 30/03/2016.

The following entry has been made in the Register of Patents:-

The Name of the patentee has been changed to:-**“Janssen R&D Ireland”**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 141786 dated 4/12/2008, Priority Date: 6/12/2007 (Europe) Granted to: - **Tibotec Pharmaceuticals Ltd, of Eastgate Village Eastgate, Little Island Co Cork Ireland.**

In pursuance of an application received on 30/03/2016.

The following entry has been made in the Register of Patents:-

The Name of the patentee has been changed to:-**“Tibotec Pharmaceuticals”**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE
OF NAME IN THE REGISTER OF PATENTS.**

In the matter of Patent No. 140069 dated 27/6/2006, Priority Date: 5/8/2005 (Spain) Granted to: - **PINTER SA, (a Spanish company), of Ctra. Manresa-Santpedor Km. 4, 6 08251 SANTPEDOR (BARCELONA), SPAIN,**

In pursuance of an application received on 27/5/2016.

The following entry has been made in the Register of Patents:-

The name of the patentee has been changed to:-**PINTER CAIPO S.A.,**

NOTIFICATION

PROCEEDING UNDER SECTION 42 OF PATENT ORDINANCE, 2000

Any person may give notice of opposition to the amendment proposed in the under mentioned patent No. 142239 dated 18/08/2014 (Priority Date: 30/03./2010 USA), lodging Form 7 of the Patent Rules, 2003 together with the prescribed fee of Rs. 1500/- at any time within two months from the date of advertisement in the Gazette, at the Patent Office, 2nd Floor Kandawala Building, M.A. Jinnah Road, Karachi.

Merck Canad Inc., a Canadian company, of 16711 Trans-Canada Highway, Kirkland, QC H9H 3L1, Canada.

SEEK TO AMEND THE Pending Patent Application No. 0571/2014 (142239) filed on 18th August 2014 as shown in strikethrough, bold and underlined in the claims pages 64-81 hereunto annexed.

**“3-(OPTIONALLY SUBSTITUTED AROMATIC AND ALIPHATIC
HYDROCARBYLOXY)-1-[5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)METHYL]-
PYRIDINE-2(1H)-ONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS”.**

The proposed amendment is desired by way of correction.

The proposed amendment may be inspected in the Patent Office.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) SECTION 37
(b) OF THE PATENTS ORDINANCE 2000**

In the matter of Patent No. 139319 of 14/7/1997 Priority date 01/8/1996 (GB). Granted to: -
**Merck Frosst Canada Inc, (a corporation duly organized under the laws of Canada), of 16711
trans-Canada Highway, City of Kirkland, Quebec, Canada.**

In pursuance of an application received on 27/5/2016.

The following entry has been made in the Register of Patents:-

**MERCK CANADA INC. (a company organized and existing under the laws of Canada),
of 16711 Trans-Canada Highway, Kirkland, Quebec, H9H 3L1, Canada, as proprietor by
virtue of Deed of Assignment dated 3rd March, 2016 made between Merck Frosst Canada Inc,
as Assignor of the One Part and MERCK CANADA INC, as assignee of the Other Part.**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE
PATENTS ORDINANCE 2000.**

In the matter of Patent No. **141786** of **04/12/2008** Priority date **06/12/2007** (Europe). Granted to: - **Tibotec Pharmaceuticals Ltd**, of Eastgate Village Eastgate, Little Island Co Cork Ireland. And later on company name was changed to **Tibotec Pharmaceuticals** and again company name was changed to **Janssen R&D Ireland**.

In pursuance of an application received on 30/03/2016.

The following entry has been made in the Register of Patents:-

Janssen Sciences Ireland UC, a Private unlimited liability company incorporated under the law of Ireland with registered number 285805 of Eastgate Village Eastgate Little Island Co Cork Ireland (“JRD”), as proprietor by virtue of Deed of Assignment dated 13/08/2015 made between **Janssen R&D Ireland**, as Assignor of the One Part and **Janssen Sciences Ireland UC**, as assignee of the Other Part.

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Applicant
<u>30/01/2017</u>			
1.	18630	Bus (Class-01)	Master Enterprises (Pvt.) Ltd.,
2.	18631	Dashboard (Class-03)	Master Enterprises (Pvt.) Ltd.,
3.	18632	Cloth (Class-13)	Al-Rehmat Apparels (Pvt.) Ltd.
4.	18633	Plastic Bottle (Class-03)	M/s. Pro Foods
5.	18634	Hand And Manual Brake Set (Class-01)	Automotive Engineering (Pvt.) Ltd.
<u>31/01/2017</u>			
6.	18635	Chemical Diffusing Apparatus (Class-07)	Unilever PLC, (A Company Registered in England and Wales Under Company)
7.	18636	Bus (Class-01)	Toyota Jidosha Kabushiki Kaisha
8.	18637	Bus (Class-01)	Toyota Jidosha Kabushiki Kaisha
<u>01/02/2017</u>			
9.	18638	Saudilube Engine Oil Plastic Can (Class-03)	Punjab Petroleum Industries (Pvt) Ltd. Oil Companies.
<u>02/02/2017</u>			
10.	18639	Award (Class-03)	Society for I AM Karachi
11.	18640	Sports Ball (Class-06)	Mikasa Corporation (Japanese Corporation)
12.	18641	Deep Freezer (Class-01)	Varoline Amter Cool Ltd.
<u>03/02/2017</u>			
13.	18642	Terminal Device (Class-01)	HUAWEI TECHNOLOGIES CO., LTD



(Dr. Muhammad Fayyaz Ahmad)
 Controller of Patents
 & Registrar of Designs
 Ph: 99215488